Kunwar Aakanksha, Krishna N Gondaliya, Khedkar Vijay M, Jha Prakash C
School of Applied Material Sciences, Central University of Gujarat, Gandhinagar, Gujarat, 382030, India.
School of Pharmacy, Vishwakarma University, Pune, Maharashtra, 411048, India.
Curr HIV Res. 2025;23(2):85-98. doi: 10.2174/011570162X360219250206082406.
The rapid increase in incidences of drug resistance and off-target toxicity in the case of Human Immunodeficiency Virus (HIV) has increased the demand for drugs with fewer side effects. HIV-1 Integrase (IN) is a promising target that helps integrate viral DNA with human DNA. It acts as a target for strand transfer inhibitors. However, the emergence of resistant mutations in the proteins necessitates the exploration of potent allosteric drugs. The allosteric integrase inhibitors (ALLINI) that interrupt the association of the integrase binding domain of the lens epithelium growth factor (LEDGF/p75) and LEDGF/p75 binding site of the IN are more promising as they hinder site specificity and viral replication.
In this study, a 3D-QSAR, molecular docking, and ADMET were carried out to investigate the binding of the C2-pyrazolopyrimidine amides and amide isosteres.
The 3D-QSAR model was developed using a series of 24 C-2 substituted pyrazolopyrimidine and amide isosteres. A statistically significant model was constructed, showing the determination coefficient (r2) and five-fold cross-validation (q2) at 0.946 and 0.506, respectively. Furthermore, the contour maps of the electrostatic potential and van der Waals coefficient provided structural modifications in the features to improve the inhibitory activity.
A molecular docking study was also performed to check the binding of the compounds to the LEDGF/p75 binding site of the IN, along with ADMET evaluation.
The outcome of the study will help to prepare the potent molecules with enhanced allosteric inhibitory activity.
人类免疫缺陷病毒(HIV)耐药性和脱靶毒性发生率的迅速增加,使得对副作用更少的药物的需求不断上升。HIV-1整合酶(IN)是一个有前景的靶点,有助于将病毒DNA与人类DNA整合。它是链转移抑制剂的作用靶点。然而,蛋白质中耐药突变的出现使得有必要探索有效的变构药物。变构整合酶抑制剂(ALLINI)能够中断晶状体上皮生长因子(LEDGF/p75)的整合酶结合域与IN的LEDGF/p75结合位点之间的关联,因其阻碍位点特异性和病毒复制而更具前景。
在本研究中,进行了三维定量构效关系(3D-QSAR)、分子对接和药物代谢及毒性预测(ADMET)研究,以考察C2-吡唑并嘧啶酰胺和酰胺电子等排体的结合情况。
使用一系列24种C-2取代的吡唑并嘧啶和酰胺电子等排体建立3D-QSAR模型。构建了一个具有统计学意义的模型,其决定系数(r2)和五重交叉验证(q2)分别为0.946和0.506。此外,静电势和范德华系数的等高线图提供了结构特征方面的修饰,以提高抑制活性。
还进行了分子对接研究,以检查化合物与IN的LEDGF/p75结合位点的结合情况,并进行了ADMET评估。
该研究结果将有助于制备具有增强变构抑制活性的强效分子。